BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
UBS
Accenture
McKinsey
Daiichi Sankyo
Colorcon
Cerilliant
Express Scripts
US Department of Justice
Merck

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,229,607

« Back to Dashboard

Summary for Patent: 7,229,607
Title:Treatment of respiratory disease
Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
Inventor(s): Bannister; Robin Mark (Essex, GB), Richards; Andrew John McGlashan (Cambridge, GB), Gilbert; Julian Clive (Essex, GB), Morton; David A. V. (Bath, GB), Staniforth; John (Bath, GB)
Assignee: Sosei R&D Ltd (GB)
Application Number:10/266,717
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 7,229,607

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sunovion Pharms Inc SEEBRI glycopyrrolate POWDER;INHALATION 207923-001 Oct 29, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ➤ Subscribe
Sunovion Pharms Inc UTIBRON glycopyrrolate ; indacaterol maleate POWDER;INHALATION 207930-001 Oct 29, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,229,607

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0008660.3Apr 7, 2002

Non-Orange Book US Patents Family Members for Patent 7,229,607

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,736,670 Method of making particles for use in a pharmaceutical composition ➤ Subscribe
8,303,991 Method of making particles for use in a pharmaceutical composition ➤ Subscribe
9,585,839 Particles for use in a pharmaceutical composition ➤ Subscribe
6,884,794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets ➤ Subscribe
8,048,451 Pharmaceutical compositions for inhalation ➤ Subscribe
8,932,635 Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation ➤ Subscribe
8,871,274 Pharmaceutical formulations for dry powder inhalers ➤ Subscribe
8,435,567 Pharmaceutical compositions of hydrophobic surface-modified active substance microparticles for inhalation ➤ Subscribe
8,580,306 Particles for use in a pharmaceutical composition ➤ Subscribe
8,956,661 Method of making composite particles for use in pharmaceutical compositions and composite particles and compositions thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,229,607

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2283817 ➤ Subscribe
Canada 2405767 ➤ Subscribe
Canada 2406119 ➤ Subscribe
Canada 2406201 ➤ Subscribe
Canada 2406206 ➤ Subscribe
Canada 2413692 ➤ Subscribe
Canada 2429665 ➤ Subscribe
China 1422154 ➤ Subscribe
China 1292745 ➤ Subscribe
China 1424909 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Boehringer Ingelheim
Chubb
Novartis
Chinese Patent Office
Colorcon
Cerilliant
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot